Genetic Testing Market Outlook Signals Expansion To $32.21 Billion Through 2030

The genetic testing market is gaining significant momentum as advancements in healthcare and personalized medicine continue to drive demand. With more emphasis on early diagnosis, preventive care, and tailored treatment plans, this sector is poised for substantial growth in the coming years. Below, we explore the market size projections, key players, emerging trends, and detailed segment breakdowns shaping the future of genetic testing.

Projected Growth and Size of the Genetic Testing Market by 2030
The genetic testing market is anticipated to experience robust expansion, reaching a valuation of $32.22 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 8.9% over the forecast period. Several factors contribute to this upward trajectory, including the rising importance of personalized medicine, the incorporation of genetic information into clinical decision-making, an increasing prevalence of chronic diseases, and the broadening scope of preventive healthcare initiatives. Additionally, enhanced genetic counseling services are playing a vital role in supporting this market's development. Key trends expected to drive growth include widespread adoption of predictive genetic testing, expansion in prenatal and newborn screening programs, growing demand for pharmacogenomics testing, advancements in cancer genetic diagnostics, and the rising availability of direct-to-consumer genetic testing options.

The genetic testing market size has grown strongly in recent years. It will grow from $20.84 billion in 2025 to $22.91 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to advancements in molecular biology, declining dna sequencing costs, increased awareness of genetic disorders, expansion of diagnostic laboratories, early adoption in oncology.

Download a free sample of the genetic testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6729&type=smp&utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Prominent Companies Leading the Genetic Testing Market
The genetic testing landscape is shaped by a number of influential companies, including Myriad Genetics Inc, Illumina Inc, Abbott Laboratories, Eurofins Scientific, Danaher Corporation, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, Qiagen NV, Thermo Fisher Scientific Inc., BioRad Laboratories Inc., BGI, Berry Genomics Co. Ltd, Daan Gene Co. Ltd, Annoroad Gene Technology Co. Ltd, Igenomix, Circle DNA, Centogene, Probably Genetic, Genome Biologics, WuXi NextCODE, Genomtec, Testgene, Evogen Lab, Phosphorus, Helix, 10x Genomics, Quantgene, DNALabs, Deep Genomics, Hologic Inc, Molecular Biology & Genetics Laboratory, IVI MIDDLE EAST FERTILITY CLINIC, and Bio Certica. These organizations are at the forefront of innovation, offering a broad array of genetic testing services and driving technological progress within the industry.

Strategic Acquisition to Strengthen Genetic Testing Capabilities
In a significant move during February 2025, Tempus, a US-based provider specializing in precision medicine solutions and AI-driven clinical insights, acquired Ambry Genetics. Although the financial details of the deal remain undisclosed, the acquisition aims to bolster Tempus' genetic testing portfolio by integrating Ambry's expertise in hereditary disease testing into its precision medicine platform. Ambry Genetics, known for its services in hereditary cancer, cardiovascular, pediatric, and rare disease genetic testing, enhances Tempus' technological capabilities and market presence in the clinical genetic diagnostics space.

View the full genetic testing market report:
https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report?utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Innovations and Technological Advances Shaping Genetic Testing Trends
Leading genetic testing companies are increasingly concentrating on developing cutting-edge solutions such as AI-driven genomic interpretation algorithms. These tools help address the growing need for more accurate variant classification, improved diagnostic precision, and expanded diversity in precision healthcare approaches. By analyzing massive genetic datasets, AI-based interpretation systems can identify disease-causing variants more quickly and reliably than traditional methods, reducing uncertainty and accelerating clinical decision-making. For example, in June 2023, Illumina, Inc., a prominent U.S. biotechnology firm, introduced PrimateAI-3D-an AI algorithm that predicts pathogenic genetic mutations using a 3D structural analysis of proteins alongside evolutionary data from primates. This innovation enhances large-scale genomic interpretation, speeds up precision medicine efforts, and refines diagnostic workflows by enabling clinicians and researchers to better assess genetic risks, ultimately strengthening overall genetic testing effectiveness.

Detailed Breakdown of the Genetic Testing Market Segments
The genetic testing market is organized into several distinct segments, which offer a clearer view of where demand and innovation are concentrated:
1) By Type: Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomics Testing, Nutrigenomic Testing, and Other Types.
2) By Technology: Cytogenetic Testing, Biochemical Testing, Molecular Testing.
3) By Application: Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Other Applications.
4) By End User: Hospitals and Clinics, Diagnostic Laboratories and Centres, and Other End Users.

Each primary category also includes specific subsegments, highlighting detailed areas of focus:
- Predictive Testing breaks down into Genetic Risk Assessment and Family History-Based Testing.
- Carrier Testing includes Single Gene Carrier Testing and Expanded Carrier Screening.
- Prenatal and Newborn Testing covers Non-Invasive Prenatal Testing (NIPT) and Newborn Screening Tests.
- Diagnostic Testing is divided into Confirmatory Genetic Testing and Clinical Diagnostic Testing.
- Pharmacogenomics Testing focuses on Drug Response Testing and Adverse Drug Reaction Testing.
- Nutrigenomic Testing includes Dietary Response Testing and Metabolism Testing.
- Other Types consist of Ancestry Testing and Whole Genome Sequencing.

This thorough segmentation provides a comprehensive understanding of the market's diverse opportunities and areas of growth potential as genetic testing continues to evolve.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.